News
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than 57%. And since the beginning of 2025, the company’s share price has declined more than 35%. As of the time of this writing, NVO shares are down just over 20% this morning to $55.17 per share.
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors ...
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Novo Nordisk A/S shares plunged after a Q2 revenue update and 2025 guidance downgrade. Click here to find out why NVO stock ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
5h
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback